Niederberger V, et al. - In patients with grass pollen–induced rhinitis and controlled asthma, the safety and clinical efficacy of immunotherapy (allergen immunotherapy) with BM32 were assessed. In addition, to well tolerability, injections of BM32 resulted in induction of allergen-specific IgG and improved clinical symptoms of seasonal grass pollen allergy.